BidaskClub Upgrades Kura Oncology (KURA) to Strong-Buy

BidaskClub upgraded shares of Kura Oncology (NASDAQ:KURA) from a buy rating to a strong-buy rating in a research report released on Friday morning.

Several other analysts have also recently issued reports on KURA. ValuEngine upgraded shares of Kura Oncology from a hold rating to a buy rating in a research note on Wednesday, November 7th. began coverage on shares of Kura Oncology in a report on Monday, November 5th. They set a buy rating and a $35.00 target price on the stock. HC Wainwright set a $31.00 target price on shares of Kura Oncology and gave the company a buy rating in a report on Thursday, November 1st. Cowen reissued a buy rating on shares of Kura Oncology in a report on Monday, October 22nd. Finally, Zacks Investment Research raised shares of Kura Oncology from a sell rating to a buy rating and set a $18.00 price target on the stock in a report on Tuesday, October 16th. One analyst has rated the stock with a sell rating, seven have assigned a buy rating and one has given a strong buy rating to the company. The stock presently has an average rating of Buy and a consensus price target of $28.17.

Shares of NASDAQ KURA opened at $16.76 on Friday. The company has a current ratio of 14.76, a quick ratio of 14.76 and a debt-to-equity ratio of 0.02. Kura Oncology has a 1-year low of $10.20 and a 1-year high of $24.02. The stock has a market cap of $626.47 million, a PE ratio of -11.03 and a beta of 3.16.

Kura Oncology (NASDAQ:KURA) last issued its quarterly earnings data on Monday, November 5th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.41) by $0.01. Equities analysts anticipate that Kura Oncology will post -1.72 EPS for the current year.

In related news, major shareholder Ecor1 Capital Fund Qualified, bought 40,538 shares of the stock in a transaction dated Thursday, December 13th. The shares were purchased at an average price of $13.90 per share, with a total value of $563,478.20. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 15.30% of the stock is currently owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. BlackRock Inc. raised its stake in shares of Kura Oncology by 19.7% in the third quarter. BlackRock Inc. now owns 2,396,137 shares of the company’s stock valued at $41,932,000 after acquiring an additional 393,872 shares during the period. Eagle Asset Management Inc. boosted its holdings in shares of Kura Oncology by 51.4% in the 3rd quarter. Eagle Asset Management Inc. now owns 2,070,417 shares of the company’s stock valued at $36,232,000 after buying an additional 703,282 shares in the last quarter. Victory Capital Management Inc. raised its position in shares of Kura Oncology by 3.2% in the 3rd quarter. Victory Capital Management Inc. now owns 1,536,310 shares of the company’s stock valued at $26,885,000 after purchasing an additional 47,070 shares during the last quarter. Carillon Tower Advisers Inc. raised its position in shares of Kura Oncology by 62.2% in the 3rd quarter. Carillon Tower Advisers Inc. now owns 1,502,217 shares of the company’s stock valued at $26,288,000 after purchasing an additional 576,221 shares during the last quarter. Finally, Vanguard Group Inc raised its position in shares of Kura Oncology by 2.1% in the 3rd quarter. Vanguard Group Inc now owns 1,455,818 shares of the company’s stock valued at $25,477,000 after purchasing an additional 29,785 shares during the last quarter. 79.28% of the stock is currently owned by institutional investors.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancers. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.

Read More: Tariff

Analyst Recommendations for Kura Oncology (NASDAQ:KURA)

Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply